Corporate Events

From July 1, 2026 to September 30, 2026, the company has repurchased 230,000 shares, representing 0.65% for ¥737.74 million. With this, the company has completed the repurchase of 325,900 shares, representing 0.92% for ¥1,054.9 million under the buyback announced on March 30, 2026.

Mochida Pharmaceutical Co., Ltd., ¥ 42.5, Cash Dividend, Sep-29-2026

From April 1, 2026 to June 30, 2026, the company has repurchased 95,900 shares, representing 0.27% for ¥317.16 million. With this, the company has completed the repurchase of 95,900 shares, representing 0.27% for ¥317.16 million under the buyback announced on March 30, 2026.

Mochida Pharmaceutical Co., Ltd. reported earnings results for the full year ended March 31, 2026. For the full year, the company reported sales was JPY 116,951 million. Net income was JPY 7,903 million. Basic earnings per share from continuing operations was JPY 222.96.

From March 30, 2026 to March 31, 2026, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for ¥0 million under the buyback announced on March 30, 2026.

Mochida Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales to be JPY 126,000 million, Operating profit to be JPY 10,500 million, Profit attributable to owners of parent to be JPY 10,000 million, Basic earnings per share to be JPY 282.09.

Mochida Pharmaceutical Co., Ltd. provided dividend guidance for the second quarter of year ending March 31, 2027 and year ending March 31, 2027. For the second quarter, the company expects to pay a dividend of JPY 42.50 per share as compared to JPY 40.00 per share in the previous year. For the year, the company expects to pay a dividend of JPY 42.50 per share as compared to JPY 40.00 per share in the previous year.

Mochida Pharmaceutical Co., Ltd. at the AGM to be held on June 25, 2026 proposed dividend of JPY 40.00 per share for the year ended March 31, 2026 as compared to JPY 40.00 per share in the previous year, payable on June 26, 2026.

Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026

Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026.

Mochida Pharmaceutical Co., Ltd., Board Meeting, May 15, 2026. Agenda: To consider the Notice Concerning Changes in Directors.

Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026

Mochida Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering. Security Name: shares Security Type: Common Stock Securities Offered: 1,153,600

Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury.

The Board of Directors of Mochida Pharmaceutical Co., Ltd. has authorized a buyback plan on March 30, 2026.

Mochida Pharmaceutical Co., Ltd., Board Meeting, Mar 30, 2026. Agenda: To consider resolution regarding secondary offering of shares of the company's common stock; and to consider resolution to succeed the manufacturing and marketing approval for "URECE Tablets" for which FUJI YAKUHIN CO., LTD. currently holds the manufacturing and marketing approval in Japan, and to acquire assets related to the Product, including intellectual property rights such as patent rights and trademark rights.

Mochida Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expects net sales to be JPY 115,500 million. Operating profit to be JPY 9,500 million. Profit attributable to owners of parent to be JPY 8,400 million. Basic earnings per share to be JPY 236.95 against previous guidance of net sales to be JPY 110,500 million. Operating profit to be JPY 7,000 million. Profit attributable to owners of parent to be JPY 5,400 million. Basic earnings per share to be JPY 152.33. Reason for revision: Regarding the full-year financial results forecasts, the pharmaceutical business has continued to perform steadily, and net sales and operating profit are now expected to exceed the previously announced forecast. In addition, mainly due to equity-method investment income, ordinary profit and profit attributable to owners of parent are also expected to surpass the earlier forecast. In light of the above, the Company has revised upward its consolidated financial results forecasts for the full year, previously announced on May 12, 2025, for net sales, operating profit, ordinary profit, and profit attributable to owners of parent, as described above.

Mochida Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 87,487 million compared to JPY 80,731 million a year ago. Net income was JPY 6,342 million compared to JPY 5,605 million a year ago. Basic earnings per share from continuing operations was JPY 178.91 compared to JPY 158.11 a year ago.

Mochida Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 12, 2026. This event was calculated by S&P Global (Created on February 9, 2026).

Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. announced that they have entered into a license agreement to provide access to Bonjesta®? (hereinafter "the product") in Japan. Under this agreement, the companies will collaborate closely with the objective of making this product available for women in Japan, with Mochida conducting the necessary research activities required to obtain regulatory approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Bonjesta®? is a formulation developed by Duchesnay to manage nausea and vomiting of pregnancy (NVP), a common condition affecting more than half of Japanese pregnant women1) for which there are no approved medications in Japan. Recently, the Ministry of Health, Labour and Welfare of Japan has called for companies to develop this product following a request from the Japan Society of Obstetrics and Gynecology to address the issue of "drug loss", a situation where drugs approved in Europe and the United States are not developed in Japan. The product, an oral combination formulation containing doxylamine succinate and pyridoxine hydrochloride as active ingredients, is approved in 43 countries and states worldwide, namely in the USA following FDA approval in 2016 and subsequently in Europe in 2023. With long-term combined experience in women's health, Mochida and Duchesnay hope to contribute to further improving women's quality of life by introducing the product to the Japanese market.

Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026

Mochida Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Mar-30-2026

Mochida Pharmaceutical Co., Ltd. expected to report Q3 2026 results on February 6, 2026. This event was calculated by S&P Global (Created on November 4, 2025).